Pharmaceuticals Specialty: M&A Activity Will Continue to Drive Investor Interest
Evercore ISI's Umer Raffat, the sector's No. 1 analyst, is unabashedly bullish on speciality pharmaceuticals manufacturers, citing reasonable valuations and a high number of takeover targets.

Visit the full ranking of this year's All-America Research Team. Also, don't miss the All-America Research Team Hall of Fame, the All-America Sales Team and the All-America Research Team Rising Stars.

Related Articles

art-walmart-taub-0605.jpg

Stephen Taub
Illustrations by II; Bloomberg photos

Amy Whyte